Trials of full dose concurrent chemoradiotherapy in NSCLC
| Reference | No | Sample | Treatments | Median survival (months) | p value |
|---|---|---|---|---|---|
| C-R=sequential chemoradiotherapy; CR=concurrent chemoradiotherapy; R=radiotherapy; hfR=hyperfractionated radiotherapy. | |||||
| Blanke73 | 240 | Unresectable or inoperable | CR | 10 | 0.35 |
| R | 11 | ||||
| Furuse38 | 314 | Unresectable CS III | CR | 17 | 0.04 |
| C-R | 13 | ||||
| Curran39 | 611 | CS II–III | CR | 17 | 0.08 |
| ChfR | 16 | ||||
| C-R | 15 | ||||
| Mornex74 | 212 | CS IIIAN2–IIIB | CR | 16 | 0.55 |
| C-R | 14 | ||||